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Abstract 
 
Registration is a necessary step which follows every pharmaceutical preparation before being 
sent to the market and becoming available to patients. The approval follows two stages, the 
first clinical stage which provides security, safety and optimization of dosage integratively used 
in the four steps of clinical trials, and the second phase that provides marketing authorization. 
There are four agencies which operate with the procedure for approval and regulation of drugs: 
EU Legislation - Eudralex, European Directorate for the Quality of Medicines and Healthcare 
(EDQM), European Medicines Agency (EMA), Heads of Medicines Agencies (HMA) in the 
European Union. 
Objectives – Literature review of drugs registration procedure in our country and its connection 
to the form and content in the available literature documentation for the medicines registration 
in the European Union. 
Materials and methods - Comparative methods are used to compare the available literature 
data on the registration of medicines. Used data is from the guide on the form and content of 
the common technical document (Presentation and format of the dossier Common Technical 
Document (CTD) Volume 2B) and the Law on medicines and medical devices in the Republic 
of Macedonia. 
Results - The main difference between the European and Macedonian legislation for the 
registration of medicines is that the European legislation through extensive guides, closely 
defines every part of the documentation. The entire documentation should be submitted in the 
format designated as common technical document, whose form and content is on the EMA 
website with a guide of 303 pages. Here, we explain each module in a detailed manner, 
ranging from font, text size, the length of the text, to the content of each section. Thus, each 
application takes the form of a standardized and uniform document. On the other hand, in the 
Republic of Macedonia there are no such guides, so the applications can exhibit significant 
variations in form and content. 
Conclusion - Registered drugs in the country are registered under the national procedure for 
the registration of medicines in the country, according to the Law on medicines and medical 
devices. The national procedure is controlled by the Drug Bureau. The Republic of Macedonia 
needs to adopt guidelines as bylaws with exactly defined form and content of each part of the 
documentation. 
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